To Study the Efficacy, Safety and Pharmacokinetics of COVID-globulin, in Addition to Standard Therapy for the Treatment of Patients With a Moderate COVID-19 Form
试验速览
- 阶段
- 2 期
- 发起方
- Microgen
- 入组人数
- 376
- 试验地点
- 21
- 主要终点
- The proportion of subjects in the study groups in whom, during the first 7 days after drug administration, one of the following events developed according to the laboratory-instrumental methods or on the basis of a clinical presentation
研究概览
简要总结
Study of safety, efficacy and pharmacokinetics, dose selection
详细描述
Objective:
To study the efficacy, safety and pharmacokinetics of COVID-globulin, in addition to standard therapy for the treatment of patients with a moderate COVID-19 form.
Study Objectives:
The study comprises two stages, 1 and 2. Stage 1 tasks
- to determine and compare the safety parameters of COVID-globulin after a single infusion at doses of 1 mL/kg, 2 mL/kg, 4 mL/kg and placebo in addition to standard therapy in the treatment of patients with COVID-19;
- to determine and compare the efficacy parameters of COVID-globulin after a single infusion at doses of 1 mL/kg, 2 mL/kg, 4 mL/kg and placebo in addition to standard therapy in the treatment of patients with COVID-19;
- to determine the optimal therapeutic dose of COVID-globulin for the treatment of patients with moderate COVID-19 by comparing the safety and efficacy parameters of doses of 1 mL/kg, 2 mL/kg, 4 mL/kg and placebo;
- to study the pharmacokinetic parameters of COVID-globulin in the blood plasma of patients after a single infusion at a dose of 1 mL/kg, 2 mL/kg, 4 mL/kg, in addition to standard therapy for the treatment of patients with moderate COVID-19.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who are able to sign the informed consent form to partic-ipate in the clinical study;
- •Patients of both sexes at the age of 18-65 years of age;
- •Positive SARS-CoV-2 RNA test result obtained by PCR during the current episode of COVID-19 disease;
- •One or more clinical manifestations of ARI (acute respiratory infection) or patient complaints: cough (dry or scanty sputum), edema (including during exercise), chest congestion, sore throat, nasal congestion, or mild rhinorrhea, impairment or loss of smell (hyposmia or anosmia), loss of taste (dysgeusia), conjunctivitis, weakness, muscle pain, headache, vomiting, diarrhea, skin manifestations).
- •Patients with a moderate course of COVID-19, determined on the basis of at least one of the criteria specified in the Interim Guide-lines of the Ministry of Health (assessed from the moment of mani-festation of the disease symptoms):
- •Body Т > 38 °C
- •RR > 22/min
- •SpO2 < 95 % (at the atmospheric air)
- •CRP of the blood serum > 10 mg/L
- •CT changes typical of viral lesions (minimal or moderate lesion vol-ume; CT 1-2, no more than 72 hours before screening)
- •Patients meeting the requirements of the Clinical Study Protocol;
- •Negative pregnancy test (for women with preserved reproductive potential).
排除标准
- •A history of allergic reactions to human blood products;
- •Allergic reactions to the components of the study drug;
- •Hypersensitivity to human immunoglobulin;
- •Positive direct Coombs test (antiglobulin test);
- •Condition requiring invasive oxygen support at Screening;
- •Subjects with mild, severe, extremely severe COVID-19, as well as those at an outpatient treatment and not scheduled for hospitali-zation;
- •Administration of blood products or blood derivatives within 3 months prior to enrollment;
- •Administration of any antiviral, immunomodulatory drugs after the manifestation of COVID-19 (except for those to be prescribed dur-ing the study / included in the standard therapy);
- •Pathology of the immune system (primary and secondary immu-nodeficiencies, deficiency of class A immunoglobulin (IgA) and / or the presence of IgA antibodies, autoimmune diseases);
- •Child Pugh class B and C liver cirrhosis;
- •Diabetes mellitus type
- •Diseases of the thyroid gland with decompensation.
- •Signs of severe CNS lesions (past serious brain injury, meningitis, history of ischemic stroke, encephalopathy of various etiologies, epilepsy, etc.);
- •Serious blood diseases, current or in the history (for example, baseline anemia Hb < 80, myeloid leukemia, myelodysplastic syn-drome, etc.);
- •The period after the coronary artery bypass grafting / stenting of at least 3 months prior to enrollment;
- •Malignant neoplasm of any localization at present or within 5 years before enrollment into the study, except for completely healed carcinoma in situ;
- •Conditions and diseases, other than COVID-19, known from anam-nesis, accompanied by blood hypercoagulability syndrome and a trend for thrombosis (such as sickle cell anemia, polycythemia, hemostatic disorders);
- •Severe dyslipidemia in the history;
- •Disseminated intravascular coagulation syndrome, thrombosis and thromboembolism of any localization, known from the history;
- •CKD-EPI GFR < 30 mL/min at screening;
- •History of chronic III-IV FC heart failure;
- •Pregnancy or lactation;
- •Participation in any other clinical study within the last 3 months;
- •A history of tuberculosis, cancer or a positive reaction to HIV infec-tion, hepatitis B and C, syphilis according to the history;
- •Impossibility of intravenous administration of the drug;
- •Severe visual and/or hearing impairments, severe speech impair-ments and/or other abnormalities that may prevent the patient from adequate cooperation during the study);
- •Mental diseases in the history;
- •A history of alcohol, drug or medicinal product abuse;
- •Patients who, in the opinion of the investigator, are clearly or likely to be unable to understand and evaluate the information on this study within the informed consent signing process, in particular regarding the expected risks and possible discomfort;
- •Other diseases, symptoms or conditions not listed above that can be an obstacle to participation in a clinical study in the investiga-tor's opinion.
研究组 & 干预措施
Stage 1. Group 1
Group 1 - 39 subjects who will receive a single intravenous infusion of COVID-globulin at a dose of 1 mL/kg in addition to standard therapy
干预措施: COVID-globulin (Drug)
Stage 1. Group 2
Group 2 - 39 subjects who will receive a single intravenous infusion of COVID-globulin at a dose of 2 mL/kg in addition to standard therapy
干预措施: COVID-globulin (Drug)
Stage 1. Group 3
Group 3 - 39 subjects who will receive a single intravenous infusion of COVID-globulin at a dose of 4 mL/kg in addition to standard therapy
干预措施: COVID-globulin (Drug)
Stage 1. Group 4
Group 4 - 39 subjects who will receive a single intravenous infusion of placebo at a dose of 1 mL/kg in addition to standard therapy
干预措施: Placebo (Drug)
Stage 2. Group 1
Group 1 - 110 subjects who will receive a single intravenous infusion of COVID-globulin at a dose defined at Stage 1 in addition to standard therapy
干预措施: COVID-globulin (Drug)
Stage 2. Group 2
Group 2 - 110 subjects who will receive a single intravenous infusion of placebo at a dose equal to the COVID-globulin dose in addition to standard therapy
干预措施: Placebo (Drug)
结局指标
主要结局
The proportion of subjects in the study groups in whom, during the first 7 days after drug administration, one of the following events developed according to the laboratory-instrumental methods or on the basis of a clinical presentation
时间窗: 7 days
Laboratory-instrumental methods or on the basis of a clinical presentation: * development of acute renal injury stage 2 or higher, assessed by the AKIN (Acute Kidney Injury Network) scale; * development of myocardial dysfunction or acute coronary pathology; * development of thrombolytic complications; * development of a cytokine storm; * development of an acute respiratory distress syndrome (ARDS); * an increase in the degree of lung lesion, as determined by the CT; * negative dynamics of CRP with an increase in the indicator by more than 30 % compared to the baseline value; * an increase in the D-dimer indicator by more than 2 times compared with the corresponding indicator at the time of hospitalization; * aggravation of clinical symptoms, as determined by the WHO Ordinal Scale, compared with the baseline value. (Aggravation refers to a decrease in a WHO score by 1 point or more as compared to the value at Visit 1)
次要结局
- The need for respiratory support(28 days)
- The need for invasive mechanical ventilation of the lungs, ECMO(28 days)
- All-cause mortality(28 days)
- The incidence of severe and extremely severe COVID-19 disease(28 days)
- The median time to clinical improvement on the WHO Ordinal Scale for Clinical Improvement(28 days)
- Time to cancellation of oxygen support(28 days)
- Changes in the degree of lung lesion determined by the CT(7 days)
- Duration of fever (≥ 380C), days(28 days)
- The dynamics of the decrease in points on the NEWS scale(11 days (max. 28 days))
- Dynamical CRP, ferritin, D-dimer values(10 days)
- The elimination time of the SARS-CoV-2 virus(11 days)
- The need to stay at the intensive care unit(28 days)